Gaudium IVF and Women Health LimitedQ1 FY27 Results & Financial Update
Gaudium IVF and Women Health Limited: Q1 FY27 consolidated results and company financials – revenue ₹19.38 Cr, PAT ₹1.78 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Gaudium IVF and Women Health price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Gaudium IVF and Women Health Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Gaudium IVF and Women Health Limited marked its first full quarter as a publicly listed entity with consolidated revenue from operations reaching ₹19.38 crore in Q1 FY27, representing a 9.13% year-on-year increase compared to ₹17.76 crore in Q1 FY26.
Top-line growth was supported by higher patient volumes across mature medical hubs, continued demand for advanced fertility protocols, and steady contributions from international patients seeking specialized care.
Reported profitability for the quarter experienced a contraction, with EBITDA declining by 52.96% year-on-year to ₹2.42 crore from ₹5.15 crore, pushing the reported EBITDA margin down to 12.51% from 29.02% in the corresponding period of the previous year.
Management noted that earnings were intentionally moderated by upfront operating investments made ahead of a major network expansion, encompassing pre-operational expenses for the new South Extension hub, preparatory work for Nagpur and Gurgaon facilities, and incremental clinical talent hiring.
Earnings were also impacted by technology integration costs relating to the SiD and ERICA AI-led embryology tools, combined with seasonally muted revenue absorption typical of the June quarter.
Excluding these expansion-related one-off expenditures, management estimated that normalized Q1 EBITDA would have stood at approximately ₹5.35 crore with a corresponding margin of 27.63%, aligning closely with the company's historical steady-state operating profile.
During and immediately after the quarter, the company advanced its strategic growth agenda by securing Board approval for a new full-service women's hospital in Lucknow and successfully commencing operations at its South Extension hub in New Delhi.
01 · Business model
What does Gaudium IVF and Women Health do?
Founded in 2009 and led by internationally trained infertility specialist Dr. Manika Khanna, Gaudium IVF and Women Health Limited operates as a specialized fertility and women's healthcare provider in India.
The company delivers advanced reproductive solutions and holistic care, offering services such as IVF, ICSI, IUI, fertility preservation, infertility treatments, advanced genetic testing, high-risk pregnancy care, and minimally invasive gynecological procedures.
Clinical delivery is supported by integrated pregnancy care and 24/7 patient services, combining global medical expertise with personalized treatment protocols and proprietary technology applications.
Gaudium maintains a physical footprint across key locations including Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar, serving domestic patients as well as an established stream of international clients.
02 · Historical context
What shaped the business before this quarter
Founded in 2009 by Dr. Manika Khanna, growing from a single specialized practice into a multi-city fertility and women's healthcare platform.
Expanded its operational footprint across multiple urban centres including Delhi, Mumbai, Bangalore, Patna, Ludhiana, and Srinagar prior to launching the current 19-centre expansion roadmap.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹19.38 Cr |
| Total income | ₹20.50 Cr |
| Profit before tax | ₹2.45 Cr |
| Profit after tax | ₹1.78 Cr |
| EPS | ₹0.25 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations grew 9.13% year-on-year to ₹19.38 crore, primarily driven by higher patient footfalls and procedural volumes across established mature hubs.
Growth was further sustained by strong patient adoption of advanced IVF protocols and a steady stream of international patients contributing to overall billings.
Revenue expansion was primarily driven by higher patient attendance and procedure volumes across established, mature fertility hubs within the network.
Sustained clinical demand for advanced fertility treatments and specialized reproductive solutions contributed positively to the top line.
What drove margins
EBITDA margin contracted by 1,651 basis points year-on-year to 12.51% due to pre-operational expenses for the South Extension hub and preparatory outlays for upcoming centres in Nagpur and Gurgaon.
Margins absorbed incremental hiring costs for clinical talent and integration expenses associated with the deployment of SiD and ERICA AI-powered embryology systems.
Profitability was impacted by seasonally muted revenue absorption during the first quarter across the broader network.
Margins experienced significant compression due to upfront operating expenditures incurred ahead of the FY27 hub rollout, including pre-operational costs for the South Extension facility and preparatory outlays for upcoming centres in Nagpur and Gurgaon.
Incremental hiring of specialized clinical talent ahead of new center commercialization weighed on near-term profitability.
Costs associated with deploying and integrating proprietary AI-led embryology tools (SiD and ERICA) across operating units impacted current-quarter margins.
Seasonal patterns resulted in softer revenue absorption relative to fixed overheads during the June-ended quarter.
05 · Demand, customers & order book
Where demand is coming from
The network sustained a clinical pregnancy success rate exceeding 62% on the first IVF attempt across its operational facilities.
06 · Segments, products & geography
Which parts of the business are doing the work
Geography and market mix
The Board approved the establishment and operation of 'Gaudium Women Hospital, Lucknow' via a 30-year land lease, marking the company's first operational foray into Uttar Pradesh.
The Board approved the establishment of Gaudium Women Hospital in Lucknow, Uttar Pradesh, via a 30-year land lease with a 15-year lock-in and an estimated project outlay of up to ₹15 crore, marking the company's entry into the state.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company operates a network comprising 8 hubs and 28 spokes following recent expansions.
The company's clinical network reached 8 hubs and 28 spokes following the launch of new facilities.
Projects, capex and execution
Commenced commercial operations at the new IVF Centre and Hub at South Extension Part-II, New Delhi, featuring the Gaudium Signature Lab equipped with SiD and ERICA AI embryology tools.
Commercial operations commenced at the new IVF hub in South Extension Part-II, New Delhi, featuring the Gaudium Signature Lab equipped with AI-powered embryology tools SiD and ERICA as the initial milestone of a planned 19-centre expansion.
Board approval was secured for establishing Gaudium Women Hospital, Lucknow, with an estimated project cost of up to ₹15 crore.
08 · Strategy & new businesses
How the company is trying to change its growth mix
Deepened its technological capabilities through the deployment of AI-led embryology tools (SiD and ERICA) to standardize and improve embryo selection consistency across centers.
Executing a planned 19-centre expansion comprising 10 hubs slated for FY27 (including operational South Extension, plus upcoming centers in Delhi-NCR and Nagpur), followed by 8 new centres in FY28 and 1 in FY29.
09 · Reported developments
What changed operationally
Achieved a 9.13% year-on-year increase in quarterly operating revenue to ₹19.38 crore.
Successfully launched the South Extension hub and secured land arrangements for the upcoming Lucknow women's hospital.
Reported operating revenue grew 9.13% year-on-year to ₹19.38 crore, demonstrating resilience in core mature hubs.
Successfully launched operations at the South Extension Part-II facility in New Delhi featuring advanced AI-led laboratory infrastructure.
10 · Pressure points & risks
What is not going smoothly
Reported EBITDA declined by 52.96% year-on-year to ₹2.42 crore and PAT fell by 42.27% to ₹1.8 crore due to upfront expansion investments and pre-operational expenses.
EBITDA declined 52.96% year-on-year to ₹2.42 crore and PAT fell 42.27% to ₹1.78 crore due to upfront expansion investments and pre-operational costs.
11 · Items worth noticing
The line items that can distort a quick read
Incurred pre-operational expenses for the South Extension hub, preparatory costs for Nagpur and Gurgaon, clinical talent ramp-up, and SiD/ERICA integration expenditures that depressed reported Q1 EBITDA by ~₹2.93 crore.
12 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
The company maintains a debt-light balance sheet following its initial public offering, supporting funded capital expenditure plans.
13 · Management guidance & targets
What management is targeting from here
Management confirmed plans to roll out 10 new hubs during FY27, with the South Extension hub already operational and remaining locations in Delhi-NCR and Nagpur progressing on schedule.
Management stated plans to launch 10 new hubs in FY27—of which one is operational at South Extension, with remaining locations such as Delhi-NCR and Nagpur progressing on track—followed by 8 new centres in FY28 and 1 in FY29.
14 · Beyond the numbers
What changed beyond the numbers
Reported update
Board leadership and governance updates
The company operated its first full quarter under listed company status following its initial public offering, overseen by Chairperson and Managing Director Dr. Manika Khanna and CFO Rakesh Kumar Sharma.
Reported update
Board appointment of Lucknow facility
The Board of Directors approved the establishment of a full-service women's hospital format under the name 'Gaudium Women Hospital, Lucknow' in Uttar Pradesh via a long-term lease arrangement.
15 · Key Q&A
The quarter, answered directly
What does Gaudium IVF and Women Health do?
Founded in 2009 and led by internationally trained infertility specialist Dr. Manika Khanna, Gaudium IVF and Women Health Limited operates as a specialized fertility and women's healthcare provider in India.
What is the clearest takeaway from Q1 FY27?
Gaudium IVF and Women Health Limited marked its first full quarter as a publicly listed entity with consolidated revenue from operations reaching ₹19.38 crore in Q1 FY27, representing a 9.13% year-on-year increase compared to ₹17.76 crore in Q1 FY26.
What drove revenue or demand?
Revenue from operations grew 9.13% year-on-year to ₹19.38 crore, primarily driven by higher patient footfalls and procedural volumes across established mature hubs.
What mattered most for margins or profitability?
EBITDA margin contracted by 1,651 basis points year-on-year to 12.51% due to pre-operational expenses for the South Extension hub and preparatory outlays for upcoming centres in Nagpur and Gurgaon.
What changed operationally beyond the headline numbers?
The company operates a network comprising 8 hubs and 28 spokes following recent expansions.
What is management guiding or targeting from here?
Management confirmed plans to roll out 10 new hubs during FY27, with the South Extension hub already operational and remaining locations in Delhi-NCR and Nagpur progressing on schedule.
16 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
17 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Hub rollout execution: Progress on the remaining 9 planned hub launches for FY27, including upcoming facilities in Delhi-NCR and Nagpur.
- 02
Lucknow hospital development: Execution milestones and capital deployment for the Gaudium Women Hospital project in Lucknow up to the estimated ₹15 crore outlay.
- 03
Margin normalization: Absorption of pre-operational costs and the trajectory of EBITDA margins back toward normalized steady-state levels (~27.6%) as new hubs scale operations.
- 04
Hub rollout execution: Track the physical rollout and commercial progress of remaining hubs planned for FY27, specifically in Delhi-NCR and Nagpur.
- 05
Lucknow facility development: Monitor construction milestones and regulatory approvals for the upcoming Gaudium Women Hospital in Lucknow.
- 06
Margin normalization: Observe the operating leverage and revenue absorption trajectory as newly commissioned hubs transition from pre-operational phases toward maturity.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.